Integrative array-based approach identifies MZB1 as a frequently methylated putative tumor suppressor in hepatocellular carcinoma

Satoshi Matsumura, Issei Imoto, Ken Ichi Kozaki, Takeshi Matsui, Tomoki Muramatsu, Mayuko Furuta, Shinji Tanaka, Michiie Sakamoto, Shigeki Arii, Johji Inazawa

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: The aim of this study was the identification of novel tumor suppressor genes (TSG) silenced by DNA hypermethylation in hepatocellular carcinoma (HCC). Experimental Design: We conducted integrative array-based approach for genome-wide screening of methylation targets using a methylated DNA immunoprecipitation-CpG island microarray and expression array in three universal hepatoma cell lines and normal liver tissue. Through detailed expression and functional analyses using hepatoma cell lines and primary HCC samples, we isolated novel TSGs for HCC. Results: A total of 642 genes were identified as methylated in three hepatoma cell lines but unmethylated in normal liver tissue, whereas 204 genes on autosomes were identified as genes unexpressed but restored after treatment with 5-aza-2′-deoxycytidine in these cell lines and expressed in normal tissue. Through the integration of results of the two-array analyses and further validation analyses of expression and methylation status in 17 cell lines and 30 primary tumors of hepatoma, we identified MZB1, marginal zone B and B1 cell-specific protein, encoding an endoplasmic reticulum protein, as a putative TSG frequently methylated within its CpG island in hepatoma. Among 162 patients with primary HCC, silencing of MZB1 protein was significantly and independently associated with a worse outcome. Restoration of MZB1 expression in hepatoma cells reduced cell proliferation in vitro and in vivo through G 1-arrest. Conclusions: These results suggest that methylation-mediated silencing of MZB1 expression leads to loss of its tumor-suppressive activity, which may be a factor in the hepatocarcinogenesis, and is a useful prognosticator in HCC.

Original languageEnglish
Pages (from-to)3541-3551
Number of pages11
JournalClinical Cancer Research
Volume18
Issue number13
DOIs
Publication statusPublished - 2012 Jul 1

Fingerprint

Hepatocellular Carcinoma
Neoplasms
Cell Line
Methylation
CpG Islands
decitabine
Tumor Suppressor Genes
Genes
Proteins
Liver
DNA
Immunoprecipitation
Endoplasmic Reticulum
Research Design
Cell Proliferation
Genome

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Integrative array-based approach identifies MZB1 as a frequently methylated putative tumor suppressor in hepatocellular carcinoma. / Matsumura, Satoshi; Imoto, Issei; Kozaki, Ken Ichi; Matsui, Takeshi; Muramatsu, Tomoki; Furuta, Mayuko; Tanaka, Shinji; Sakamoto, Michiie; Arii, Shigeki; Inazawa, Johji.

In: Clinical Cancer Research, Vol. 18, No. 13, 01.07.2012, p. 3541-3551.

Research output: Contribution to journalArticle

Matsumura, S, Imoto, I, Kozaki, KI, Matsui, T, Muramatsu, T, Furuta, M, Tanaka, S, Sakamoto, M, Arii, S & Inazawa, J 2012, 'Integrative array-based approach identifies MZB1 as a frequently methylated putative tumor suppressor in hepatocellular carcinoma', Clinical Cancer Research, vol. 18, no. 13, pp. 3541-3551. https://doi.org/10.1158/1078-0432.CCR-11-1007
Matsumura, Satoshi ; Imoto, Issei ; Kozaki, Ken Ichi ; Matsui, Takeshi ; Muramatsu, Tomoki ; Furuta, Mayuko ; Tanaka, Shinji ; Sakamoto, Michiie ; Arii, Shigeki ; Inazawa, Johji. / Integrative array-based approach identifies MZB1 as a frequently methylated putative tumor suppressor in hepatocellular carcinoma. In: Clinical Cancer Research. 2012 ; Vol. 18, No. 13. pp. 3541-3551.
@article{5637ba7d8b4b4e8e928b8f316e38e972,
title = "Integrative array-based approach identifies MZB1 as a frequently methylated putative tumor suppressor in hepatocellular carcinoma",
abstract = "Purpose: The aim of this study was the identification of novel tumor suppressor genes (TSG) silenced by DNA hypermethylation in hepatocellular carcinoma (HCC). Experimental Design: We conducted integrative array-based approach for genome-wide screening of methylation targets using a methylated DNA immunoprecipitation-CpG island microarray and expression array in three universal hepatoma cell lines and normal liver tissue. Through detailed expression and functional analyses using hepatoma cell lines and primary HCC samples, we isolated novel TSGs for HCC. Results: A total of 642 genes were identified as methylated in three hepatoma cell lines but unmethylated in normal liver tissue, whereas 204 genes on autosomes were identified as genes unexpressed but restored after treatment with 5-aza-2′-deoxycytidine in these cell lines and expressed in normal tissue. Through the integration of results of the two-array analyses and further validation analyses of expression and methylation status in 17 cell lines and 30 primary tumors of hepatoma, we identified MZB1, marginal zone B and B1 cell-specific protein, encoding an endoplasmic reticulum protein, as a putative TSG frequently methylated within its CpG island in hepatoma. Among 162 patients with primary HCC, silencing of MZB1 protein was significantly and independently associated with a worse outcome. Restoration of MZB1 expression in hepatoma cells reduced cell proliferation in vitro and in vivo through G 1-arrest. Conclusions: These results suggest that methylation-mediated silencing of MZB1 expression leads to loss of its tumor-suppressive activity, which may be a factor in the hepatocarcinogenesis, and is a useful prognosticator in HCC.",
author = "Satoshi Matsumura and Issei Imoto and Kozaki, {Ken Ichi} and Takeshi Matsui and Tomoki Muramatsu and Mayuko Furuta and Shinji Tanaka and Michiie Sakamoto and Shigeki Arii and Johji Inazawa",
year = "2012",
month = "7",
day = "1",
doi = "10.1158/1078-0432.CCR-11-1007",
language = "English",
volume = "18",
pages = "3541--3551",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Integrative array-based approach identifies MZB1 as a frequently methylated putative tumor suppressor in hepatocellular carcinoma

AU - Matsumura, Satoshi

AU - Imoto, Issei

AU - Kozaki, Ken Ichi

AU - Matsui, Takeshi

AU - Muramatsu, Tomoki

AU - Furuta, Mayuko

AU - Tanaka, Shinji

AU - Sakamoto, Michiie

AU - Arii, Shigeki

AU - Inazawa, Johji

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Purpose: The aim of this study was the identification of novel tumor suppressor genes (TSG) silenced by DNA hypermethylation in hepatocellular carcinoma (HCC). Experimental Design: We conducted integrative array-based approach for genome-wide screening of methylation targets using a methylated DNA immunoprecipitation-CpG island microarray and expression array in three universal hepatoma cell lines and normal liver tissue. Through detailed expression and functional analyses using hepatoma cell lines and primary HCC samples, we isolated novel TSGs for HCC. Results: A total of 642 genes were identified as methylated in three hepatoma cell lines but unmethylated in normal liver tissue, whereas 204 genes on autosomes were identified as genes unexpressed but restored after treatment with 5-aza-2′-deoxycytidine in these cell lines and expressed in normal tissue. Through the integration of results of the two-array analyses and further validation analyses of expression and methylation status in 17 cell lines and 30 primary tumors of hepatoma, we identified MZB1, marginal zone B and B1 cell-specific protein, encoding an endoplasmic reticulum protein, as a putative TSG frequently methylated within its CpG island in hepatoma. Among 162 patients with primary HCC, silencing of MZB1 protein was significantly and independently associated with a worse outcome. Restoration of MZB1 expression in hepatoma cells reduced cell proliferation in vitro and in vivo through G 1-arrest. Conclusions: These results suggest that methylation-mediated silencing of MZB1 expression leads to loss of its tumor-suppressive activity, which may be a factor in the hepatocarcinogenesis, and is a useful prognosticator in HCC.

AB - Purpose: The aim of this study was the identification of novel tumor suppressor genes (TSG) silenced by DNA hypermethylation in hepatocellular carcinoma (HCC). Experimental Design: We conducted integrative array-based approach for genome-wide screening of methylation targets using a methylated DNA immunoprecipitation-CpG island microarray and expression array in three universal hepatoma cell lines and normal liver tissue. Through detailed expression and functional analyses using hepatoma cell lines and primary HCC samples, we isolated novel TSGs for HCC. Results: A total of 642 genes were identified as methylated in three hepatoma cell lines but unmethylated in normal liver tissue, whereas 204 genes on autosomes were identified as genes unexpressed but restored after treatment with 5-aza-2′-deoxycytidine in these cell lines and expressed in normal tissue. Through the integration of results of the two-array analyses and further validation analyses of expression and methylation status in 17 cell lines and 30 primary tumors of hepatoma, we identified MZB1, marginal zone B and B1 cell-specific protein, encoding an endoplasmic reticulum protein, as a putative TSG frequently methylated within its CpG island in hepatoma. Among 162 patients with primary HCC, silencing of MZB1 protein was significantly and independently associated with a worse outcome. Restoration of MZB1 expression in hepatoma cells reduced cell proliferation in vitro and in vivo through G 1-arrest. Conclusions: These results suggest that methylation-mediated silencing of MZB1 expression leads to loss of its tumor-suppressive activity, which may be a factor in the hepatocarcinogenesis, and is a useful prognosticator in HCC.

UR - http://www.scopus.com/inward/record.url?scp=84863314557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863314557&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-1007

DO - 10.1158/1078-0432.CCR-11-1007

M3 - Article

VL - 18

SP - 3541

EP - 3551

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -